Defence Therapeutics Inc. (OTCMKTS:DTCFF – Get Free Report) was the target of a significant decline in short interest in July. As of July 15th, there was short interest totaling 6,859 shares, a decline of 33.8% from the June 30th total of 10,359 shares. Based on an average daily volume of 6,436 shares, the days-to-cover ratio is currently 1.1 days.
Defence Therapeutics Stock Performance
Shares of DTCFF opened at $0.28 on Friday. Defence Therapeutics has a 12 month low of $0.25 and a 12 month high of $0.78. The firm has a fifty day simple moving average of $0.34 and a 200 day simple moving average of $0.39.
About Defence Therapeutics
Defence Therapeutics is a clinical-stage biotechnology company focused on the development of innovative immuno-oncology therapies. Headquartered in Montreal, Canada, the company leverages its proprietary Oncoprex platform to deliver targeted immunomodulatory treatments designed to stimulate the body’s immune response against solid tumors. Its research and development efforts center on novel approaches that aim to enhance efficacy while minimizing systemic side effects commonly associated with conventional cancer therapies.
The Oncoprex platform employs a unique vectorization technology to transport immunotherapeutic agents directly into the tumor microenvironment.
See Also
- Five stocks we like better than Defence Therapeutics
- Chipotle Mexican Grill Stock Rallies as Q2 Results Top Fears, Guidance Rises
- L3Harris’ Record Backlog Makes Its Stock Sell-Off Look Overdone
- Quantum Earnings Could Decide Whether the Sector’s Sell-Off Has Gone Too Far
- Microsoft Just Flipped the AI Spending Narrative Overnight
Receive News & Ratings for Defence Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Defence Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
